Contrary to older research that showed neuroimaging emerging as the single most dominating cost contributor in ischemic stroke care for older Americans, a new study shows treatment and other line items account for bigger slices of the bill.
Contrary to older research that showed neuroimaging emerging as the single most dominating cost contributor in ischemic stroke care for older Americans, a new study shows treatment and other line items account for bigger slices of the bill.